Pre-judgment of national frontline procurement in 2020
Release date: 2020-01-13 Views: 0
2019 is a crucial year for the national drug procurement innovation and a year for major changes to be implemented. The centralized procurement of medicines has entered the era of medical insurance bureaus, and pharmaceutical companies are experiencing the pain caused by various policies and market adjustments. Demonstration price cuts for the expansion of national joint mining and strong price cuts for the special purchases of two diseases in Hebei indicate that centralized mining in 2020 is full of uncertainty. Under the new situation, as an important part of the three-medical linkage, the supply chain of drug supply is increasingly strengthening the "clinical rational use" in the overall business strategy. The change and adjustment of drug prices are also in a quiet transition period of "grasp the overall situation, grasp the key, and plan for the future". In the context of "pharmaceutical bidding + sales procurement" showing integration, combing, judging, analyzing, and responding quickly and effectively to drug procurement policies will be the decisive prerequisite for determining competition between pharmaceutical companies and who can win.
2020 will be a year of innovation in the centralized drug procurement system. With the gradual maturity of the drug's entire life-cycle regulatory governance, the era of brutal growth of the pharmaceutical industry has passed, the gray marketing model of high gross profit + high expenses is coming to an end, and the era of melee in the country's drug procurement has officially arrived.
01 High degree of procurement concentration
In the new year, in terms of varieties, it is expected that the degree of procurement concentration will be greatly enhanced, which is reflected in the three levels of catalog entry, varieties, and standardization of drugs.
In terms of directory access, the strong advancement of the National Essential Medicines Catalog 1 + X, and the three-year layout of the 442 increase in medical insurance catalogs in various provinces have brought a strong sense of oppression.
In 2020, in the new round of drug procurement in various provinces, first of all, in the process of formulating the procurement catalog, the inclusion of the medical insurance catalog and the new national essential medicine catalog has been nailed down. At the same time, the negative list-the monitoring of the transfer of species in the catalog, Equivalent to clearing again.
In addition, in 2019, the National Health and Medical Commission issued the "Notice on Promoting the Construction of a Close County Medical and Health Community" and the "Guidance Plan on the Pilot Project of Building a Close County Medical and Health Community". The relevant policies are very clear. The community means a new purchase subject and payment subject. Pharmaceutical companies will face thousands of pharmaceutical purchase and payment subjects composed of 500 counties. A series of questions such as how to enter, how to go out, when to go in, when to go out, and how to exchange space with time, test the wisdom of market entry personnel.
In terms of varieties, following the expansion of 4 + 7 and joint mining, the second round of national joint procurement has totaled 33, covering diabetes, hypertension, anti-tumor and rare diseases. In terms of volume procurement, Jiangxi's first batch of procurement catalogs was 52. In combination with the special procurement of Wuhan GPO, Henan Yang, and Hebei in 2019, it is expected that the local area will follow the national route, and first select some varieties with high purchase amounts and high impact for pilot purchases. The requirements for production enterprises are, from In terms of variety selection and layout, we must shift from the previous large and wide to fine and detailed, focus on key varieties, and strive to be the best from the aspects of raw material costs and quality management aspects such as pharmacovigilance systems.
In terms of drug standardization, in the division of the bidding group, the combination of indications and functional effects similar to the optimal combination and merging of drugs, reducing the number of bargaining product regulations, thereby blocking the odd-type monsters, will become the mainstream trend. This Wuhan GPO, oral oral release dosage form is divided into a group; the content of active ingredients is the same, different names or different acid radicals, bases, metal elements, etc. are also classified as the same drug. In fact, the medical industry has been reminded that it will be more and more difficult to avoid competition by pure specifications and levels.
02 More aggressive purchasing methods
In 2020, the provincial procurement of quantities, including the procurement of medical associations (medical institutions), will continue to strengthen, and the idea of classified procurement will continue. For products with large quantities of pharmaceutical companies, the provinces will use the National United Mining Group as a model for group purchases. Small quantities and some exclusive, patented drugs will be negotiated to determine prices or negotiate. At the same time, record-based purchases, matching transactions, and inquiry purchases will show normal steps.
The two diseases in Hebei reduced the price to a penny, and the bargaining price of some commonly used drugs in Anhui and the second batch of anti-cancer drugs was reduced by an average of 35.16%. The low value of 49% of imported products as a control price allows the transfer of products that have been traded on the same product line, and other phenomena indicate that in 2020 the city's public hospital markets in all provinces will shrink faster than the slower growth rate in the future. . The hospital will have the right to speak and decide on procurement, especially in the context of clinical pathways and payment by disease type. Resource utilization control will be more stringent. The effect will be precise and the hospital will actively participate in cost control.
Although the decline in drug prices is a trend, the author believes that drug prices do not determine everything. From the perspective of medical institutions, the priority of disease, the level of investment in resources, and the simplicity of treatment options will be the key factors that determine the clinical use of drugs. , Whose drug is cost-effective, who can be the king. Simple thinking of price reduction or price increase will also be eliminated by the trend. Facing the new era of "medical drive + market access + drug procurement", the industry has entered a period of structural adjustment and comprehensive integration, and everyone should calmly cope with relevant challenges.
03 Drug price adjustment should comply with the dual law
On November 29, 2019, the State Council's Leading Group for Deepening the Reform of the Medical and Health System officially issued "Several Policies and Measures for Further Deepening the Reform of the Medical and Health System with Centralized Purchasing and Use of Drugs as a Breakthrough" (Guo Yi Kai Fa  No. 3), On the basis of summing up and refining local experience, the "Several Policies and Measures" further clarified the direction of centralized procurement, and clarified the reform path of "making space, restructuring, and ensuring convergence", which will help guide localities to further raise awareness and strengthen confidence in medical reform. And determination, is conducive to further promote reform in key areas and key links. The volume of procurement reduces the profit space, the base medicine system reduces the use of space, the medical insurance payment restricts the payment space, the future drug price management policy reduces the adjustment space, and the public hospital purchase and sales field under study to build an integrity system and a punishment system will also regulate the behavior space.
Under the background of stock clearance, the era of low profits has come. As a pharmaceutical practitioner, I hope that pharmaceuticals will have reasonable profits, because the company must continue to develop healthily, and employees who regard the enterprise as a home want to progress and grow; as an ordinary consumer, they hope to get high-quality and cheap drugs, Relieve the pain of disease and improve the quality of life. To some extent, from the perspective of the public interest, it is indeed necessary to regulate the price of medicines.
Simply giving the drug purchase price to market supervision or administrative supervision will not really play the role of “priority on efficiency and consideration of fairness”. From the perspective of administrative management, it is more important to consider the issue from the perspective of improving the guiding basis for the allocation of price resources, which is specifically reflected in the price level. That is, blindly lowering the price of drugs is unsustainable and violates market rules. The consequence can only be to inhibit and distort the innovative development of pharmaceutical companies. The formulation of drug price policies must fully consider that it can stimulate the vitality of innovation and development of drug production enterprises while reducing the burden on the masses, and also have the logic and enforceability of policy advancement. Advancement. It is not difficult to see through the relevant measures in recent years that the path has actually already existed. The key is to see how policy makers make measures based on actual conditions and strengthen them.
- Basic introduction of Heilongjiang Hexiang Pharmaceutical Co., Ltd.
- How to contact Bermuda Medical (Shanghai) Regenerative Medicine Technology Co., Ltd.
- Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Brief introduction of Zaozhuang Yinhai Pharmaceutical Co., Ltd.
- Contact information of Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Introduction of Bermoudi (Shanghai) Regenerative Medicine Technology Co., Ltd.
- 2020年全国带量采购一线实操预判 1. Pre-judgment on the front line of national procurement in 2020
- 药店注意多款常见药修改说明书 2. Pharmacies pay attention to the revised instructions for many common drugs
- 2019年癌症领域跌下A轮融资榜首IPO市场持续升温 3. In 2019, the cancer sector fell off the top of the A round of financing. The IPO market continues to heat up.
- 首个mRNA疫苗进入2期临床研究有望降低先天缺陷 4.First mRNA vaccine enters Phase 2 clinical study expected to reduce birth defects
- 细菌感染患者使用多种抗生素可能会促进耐药性的传播 5.Use of multiple antibiotics in patients with bacterial infection may promote the spread of resistance
- 医药企业的未来——并购交易 6. The future of pharmaceutical companies-M & A transactions
- 2019年中国上市药品分析报告 7. Analysis report of Chinese marketed drugs in 2019